基于分子标的心血管疾病治疗的新见解
Armanda Wojtasińska1, Joanna Kućmierz1, Julita Tokarek1
1Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
International journal of molecular sciences
|December 9, 2023
概括
新的心血管疾病 (CVD) 治疗向分子途径,并利用诸如SGLT-2抑制剂和GLP-1受体激活剂等技术. 异构体在了解心肌损伤方面也显示出有前途,以改善心血管疾病策略.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,经常与糖尿病和脂质疾病同时发生.
- 这些并发症使预后和治疗复杂化,需要新的治疗策略.
- 新兴的研究探索新的分子标和技术来管理心血管疾病和相关疾病.
研究的目的:
- 审查心血管疾病 (CVD) 的当前和新兴治疗目标和技术.
- 突出新型治疗糖尿病和脂质失调症在心血管疾病管理中的作用.
- 探索外体在理解和治疗心肌缺血中的潜力.
主要方法:
- 关于心血管疾病,糖尿病和脂质疾病的当前文献的综述.
- 对新型分子标的分析,如PCSK9,血管蛋白样蛋白3和ATP-酸酶.
- 检查治疗技术,包括siRNA,SGLT-2抑制剂和GLP-1受体激动剂.
- 研究外体在心肌缺血和损伤中的作用.
主要成果:
- 针对PCSK9,血管蛋白样蛋白3和ATP-酸酶的新疗法正在推进失脂症治疗.
- 用于糖尿病的SGLT-2抑制剂和GLP-1受体激动剂显示出显著的心血管益处.
- 外体与心肌缺血有关,其水平与损伤严重程度相关.
结论:
- 了解新的分子机制和治疗技术对于推进心血管疾病治疗至关重要.
- 糖尿病和脂质疾病的心血管疾病的综合管理需要探索新的标和药物类别.
- 外体体对心肌损伤和心血管疾病治疗方法的未来研究是一个有前途的领域.
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:26Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
95
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
95